BiotechTube

Bremelanotide

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sexual Arousal Disorder

Conditions

Sexual Arousal Disorder

Trial Timeline

Feb 1, 2006 → May 1, 2007

NCT ID
NCT00425256

About Bremelanotide

Bremelanotide is a phase 2 stage product being developed by Pfizer for Sexual Arousal Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00425256. Target conditions include Sexual Arousal Disorder.

What happened to similar drugs?

3 of 9 similar drugs in Sexual Arousal Disorder were approved

Approved (3) Terminated (0) Active (6)
🔄DapoxetineJohnson & JohnsonPhase 3
✅sildenafilPfizerApproved
✅AlfuzosinSanofiApproved
🔄AVANAFIL + placeboSanofiPhase 3
✅Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
🔄tibolone + estradiol-norethisteroneOrganonPhase 3
🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00425256Phase 2Completed

Competing Products

18 competing products in Sexual Arousal Disorder

See all competitors
ProductCompanyStageHype Score
DapoxetineJohnson & JohnsonPhase 3
40
Gardasil VaccineMerckPre-clinical
26
sildenafilPfizerApproved
43
sildenafilPfizerPhase 2
35
CP-866,087 + CP-866,087 + CP-866,087 + PlaceboPfizerPhase 2
35
PF-00446687 + PlaceboPfizerPhase 2
35
Sildenafil 100 mg + PlaceboPfizerPhase 2
35
AlfuzosinSanofiApproved
43
AVANAFIL + placeboSanofiPhase 3
40
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
40
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
25
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
25
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
25
tibolone + estradiol-norethisteroneOrganonPhase 3
34
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
30
bremelanotidePalatin TechnologiesPhase 2
25
BremelanotidePalatin TechnologiesPhase 3
30
EVO100 + PlaceboEvofem BiosciencesPhase 3
30